← Search & browse all drugs

apraglutide

A16AX27

Forms & Strengths

Subcutaneous solution: 5 mg/0.5 mL in a single-dose pre-filled syringe

Adult Dosing

Short bowel syndrome with intestinal failure: 5 mg subcutaneously once weekly

Pediatric Dosing

Safety and effectiveness in pediatric patients have not been established

Indications

Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Mechanism of Action

Long-acting synthetic analog of glucagon-like peptide-2 (GLP-2)
Binds to GLP-2 receptors in the gastrointestinal tract, increasing intestinal blood flow
Stimulates mucosal growth, enhancing intestinal absorption of fluids, electrolytes, and nutrients

Contraindications

History of hypersensitivity to apraglutide or its excipients
Active gastrointestinal malignancy or history of GI malignancy within the past 5 years

Adverse Reactions

Abdominal pain
Nausea
Vomiting
Diarrhea
Fluid overload
Injection site reactions
Stomal complications

Drug Interactions

Oral medications with a narrow therapeutic index or rapid dissolution profiles should be monitored for altered absorption due to enhanced intestinal transit or absorptive capacity

Curated Content: Needs Vetting Before Put to Clinical Use